Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES

NCT00952380 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00952380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00952380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
March 31, 2018
Enrollment
38 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism